The Chase Group is honored to continue our partnership with Aeglea BioTherapeutics as we work to build their Rare Disease Clinical Development Leadership team. As… Continue Reading →
As a leader in engineering human enzymes to address significant unmet medical needs in rare genetic diseases and cancer, Aeglea BioTherapeutics is committed to using… Continue Reading →
The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor… Continue Reading →
The Chase Group is pleased to announce the successful completion of the Director, Clinical Research, Neuroscience at Eisai Inc. The successful candidate is a Board… Continue Reading →
Ionis Pharmaceuticals continues to partner with The Chase Group to find high caliber talent to join them in revolutionizing medicine through the discovery and development… Continue Reading →
With the relocation of their headquarters to Cambridge, MA, Ipsen US is entering a new era of innovation and growth to become a leading global… Continue Reading →
Ionis Pharmaceuticals has once again retained The Chase Group to assist them in finding high caliber talent to join their growing team. Due to exciting… Continue Reading →
The Chase Group appreciates and values our continued partnership with Ionis Pharmaceuticals and is pleased to announce the successful completion of the Vice President, Clinical… Continue Reading →
The Chase Group is proud to be working on a search for the GCP Quality Assurance and Compliance team for Ionis Pharmaceuticals. The hiring manager,… Continue Reading →
Eisai has retained The Chase Group to secure a physician for a crucial medical affairs role to serve as the Medical Lead and Subject Matter… Continue Reading →